{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T10:05:48Z","timestamp":1775469948988,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1016\/j.jaad.2009.01.008","type":"journal-article","created":{"date-parts":[[2009,5,24]],"date-time":"2009-05-24T04:53:32Z","timestamp":1243140812000},"page":"934-943","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":106,"title":["Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis"],"prefix":"10.1016","volume":"60","author":[{"given":"Lawrence","family":"Anderson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George J.","family":"Schmieder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. Philip","family":"Werschler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo H.","family":"Tschen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark R.","family":"Ling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dow B.","family":"Stough","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janelle","family":"Katsamas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2009.01.008_bib1","first-page":"1099","article-title":"The kinetics of skin cancer: progression of actinic keratosis to squamous cell carcinoma","volume":"33","author":"Fuchs","year":"2007","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jaad.2009.01.008_bib2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1365-2133.2005.07121.x","article-title":"Solar (actinic) keratosis is squamous cell carcinoma","volume":"155","author":"Ackerman","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2009.01.008_bib3","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.clindermatol.2003.12.006","article-title":"The development of actinic keratosis into invasive squamous cell carcinoma: evidence and evolving classification schemes","volume":"22","author":"Anwar","year":"2004","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaad.2009.01.008_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1067\/mjd.2000.103344","article-title":"Histopathology of incipient intraepidermal squamous cell carcinoma (\u201cactinic keratosis\u201d)","volume":"42","author":"Cockerell","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2009.01.008_bib5","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/00007611-200007000-00001","article-title":"Actinic keratosis is squamous cell carcinoma","volume":"93","author":"Lober","year":"2000","journal-title":"South Med J"},{"key":"10.1016\/j.jaad.2009.01.008_bib6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1067\/mjd.2000.103339","article-title":"The risk of progression to invasive disease","volume":"42","author":"Glogau","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2009.01.008_bib7","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/(SICI)1097-0142(19970301)79:5<920::AID-CNCR8>3.0.CO;2-F","article-title":"Metastatic cutaneous squamous cell carcinoma derived from actinic keratosis","volume":"79","author":"Dinehart","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2009.01.008_bib8","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/j.1524-4725.1998.tb04291.x","article-title":"Characteristics of office-based visits for skin cancer. Dermatologists have more experience than other physicians in managing malignant and premalignant skin conditions","volume":"24","author":"Smith","year":"1998","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jaad.2009.01.008_bib9","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/00000372-200110000-00020","article-title":"Incidental histopathologic patterns: possible evidence of \u2018field cancerization\u2019 surrounding skin tumors","volume":"23","author":"Carlson","year":"2001","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.jaad.2009.01.008_bib10","first-page":"241","article-title":"The use of topical imiquimod for the treatment of actinic keratosis: a status report","volume":"76","author":"Del Rosso","year":"2005","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2009.01.008_bib11","first-page":"296","article-title":"Therapeutic decision making in the therapy of actinic keratoses","volume":"4","author":"Spencer","year":"2005","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2009.01.008_bib12","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1158\/0008-5472.CAN-03-2837","article-title":"Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death","volume":"64","author":"Ogbourne","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaad.2009.01.008_bib13","doi-asserted-by":"crossref","first-page":"8123","DOI":"10.4049\/jimmunol.177.11.8123","article-title":"Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate","volume":"177","author":"Challacombe","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2009.01.008_bib14","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1358\/dof.2005.030.10.942816","article-title":"PEP-005","volume":"30","author":"Hampson","year":"2005","journal-title":"Drugs Future"},{"key":"10.1016\/j.jaad.2009.01.008_bib15","unstructured":"Anderson L, Welburn P. Maximum tolerated dose of PEP005 Topical Gel for the treatment of actinic keratosis [ADA Poster P1503]. Paper presented at: American Academy of Dermatology 2007 Summer Meeting, August 1-5, 2007; New York, NY."},{"key":"10.1016\/j.jaad.2009.01.008_bib16","unstructured":"Siller G, Gebauer K, Welburn P. Treatment of actinic keratosis with PEP005 Topical Gel [AAD Poster P1900]. Paper presented at: American Academy of Dermatology 2006 Summer Meeting, July 26-30, 2006; San Diego, CA."},{"key":"10.1016\/j.jaad.2009.01.008_bib17","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jaad.2007.01.047","article-title":"Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head","volume":"57","author":"Jorizzo","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2009.01.008_bib18","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jaad.2003.12.010","article-title":"Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials","volume":"50","author":"Lebwohl","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2009.01.008_bib19","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1001\/archderm.141.4.467","article-title":"Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials","volume":"141","author":"Korman","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2009.01.008_bib20","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/archderm.140.7.813","article-title":"Effect of a 1-week treatment with 0.5% topical fluorouracil on occurrence of actinic keratosis after cryosurgery: a randomized, vehicle-controlled clinical trial","volume":"140","author":"Jorizzo","year":"2004","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2009.01.008_bib21","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/S0149-2918(02)80012-1","article-title":"Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis","volume":"24","author":"Loven","year":"2002","journal-title":"Clin Ther"},{"key":"10.1016\/j.jaad.2009.01.008_bib22","first-page":"144","article-title":"Comparison of 5% 5-fluorouracil cream and 5% imiquimod cream in the management of actinic keratoses on the face and scalp","volume":"6","author":"Tanghetti","year":"2007","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2009.01.008_bib23","doi-asserted-by":"crossref","first-page":"346","DOI":"10.4103\/0378-6323.27749","article-title":"Efficacy of 3% diclofenac gel for the treatment of actinic keratoses: a randomized, double-blind, placebo controlled study","volume":"72","author":"Fariba","year":"2006","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.jaad.2009.01.008_bib24","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1046\/j.1365-4362.2001.01324.x","article-title":"Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses","volume":"40","author":"Wolf","year":"2001","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2009.01.008_bib25","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1046\/j.1365-2133.2002.04561.x","article-title":"Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel","volume":"146","author":"Rivers","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2009.01.008_bib26","unstructured":"Wellburn P, Dosik JS. Skin sensitization potential of PEP005 topical gel. Presented at: 65th Annual AAD Meeting; February 1-5, 2007; Washington, DC."}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962209000334?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962209000334?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:14:09Z","timestamp":1759270449000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962209000334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["S0190962209000334"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2009.01.008","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2009.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}